SEC Form 4 · accession 0001178913-26-004259
Evogene Ltd. · EVGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gabi Tarcic
Officer — Chief Development Officer
Period of report
Jun 4, 2026
Accepted (ET)
Aug 26, 2026 · 4:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001574565
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jun 4, 2026 | P | 1,129 | $0.60 | A | 1,129 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $2.305 | holding | — | — | — | — | Nov 20, 2034 | Ordinary Shares | 40,000 | 40,000 | D |
Explanation of responses
- F1The options reported in this row vest over a period of four years, with 25% vesting upon the first anniversary of the November 20, 2024 grant date, and the remainder vesting on an equal quarterly basis (6.25% per quarter) over the following twelve quarters, such that all options will be fully vested on the four-year anniversary of the November 20, 2024 grant date.
- F2There were no transactions in the securities reported in this row, and the Reporting Person's holdings in these securities is being provided for informational purposes only.
Remarks
Exhibit 24.1 - Power of Attorney.